Humoral Response in Hemodialysis Patients Following COVID-19 Vaccination and Breakthrough Infections during Delta and Omicron Variant Predominance.

Rajkumar ChinnaduraiHenry H L WuEleanor CoxJayne MooreToni CloughElizabeth LamertonRosie DonneEdmond O'RiordanDimitrios Poulikakos

Published in: Vaccines (2022)

The vast majority of HD patients who received two doses of the Pfizer BioNTech BNT162b2 or Oxford AstraZeneca ChAdOx1 nCoV-19 vaccinations developed detectable antibody responses. Our results support the value of booster vaccination with mRNA-based COVID-19 vaccine in HD patients and highlight the need for ongoing surveillance programmes with rRT-PCR and antibody testing for timely detection of positive cases.

Keyphrases

coronavirus disease
sars cov
end stage renal disease
ejection fraction
chronic kidney disease
newly diagnosed
immune response
public health
peritoneal dialysis
prognostic factors
patient reported outcomes
loop mediated isothermal amplification
quantum dots